These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27226129)

  • 21. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
    Baetz T; Belch A; Couban S; Imrie K; Yau J; Myers R; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R; Crump M
    Ann Oncol; 2003 Dec; 14(12):1762-7. PubMed ID: 14630682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
    Crump M; Baetz T; Couban S; Belch A; Marcellus D; Howson-Jan K; Imrie K; Myers R; Adams G; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R
    Cancer; 2004 Oct; 101(8):1835-42. PubMed ID: 15386331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma.
    Zhong DT; Shi CM; Chen Q; Huang JZ; Liang JG
    Ann Hematol; 2012 Nov; 91(11):1757-63. PubMed ID: 22790106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL.
    el Aziz LM
    Med Oncol; 2014 Nov; 31(11):244. PubMed ID: 25294423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.
    Cheung MC; Hay AE; Crump M; Imrie KR; Song Y; Hassan S; Risebrough N; Sussman J; Couban S; MacDonald D; Kukreti V; Kouroukis CT; Baetz T; Szwajcer D; Desjardins P; Shepherd L; Meyer RM; Le A; Chen BE; Mittmann N;
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25868579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.
    Kim KH; Joo YD; Sohn CH; Shin HJ; Chung JS; Cho GJ; Shin SH; Kim YS; Lee WS
    Korean J Intern Med; 2009 Mar; 24(1):37-42. PubMed ID: 19270480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma.
    Morschhauser F; Depil S; Jourdan E; Wetterwald M; Bouabdallah R; Marit G; Solal-Céligny P; Sebban C; Coiffier B; Chouaki N; Bauters F; Dumontet C
    Ann Oncol; 2007 Feb; 18(2):370-5. PubMed ID: 17074972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Gemcitabine combined with cisplatin and methylprednisolone sodium succinate in chemotherapy for relapsed or refractory T cell non-Hodgkin lymphoma].
    Zhao S; Zhang QY; Sun WZ
    Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):316. PubMed ID: 20510089
    [No Abstract]   [Full Text] [Related]  

  • 29. Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?
    Todd T; Raj S; Camilleri D; Stafford G; Bulusu R; Follows G; Williams M; Marcus R
    Ann Hematol; 2009 Nov; 88(11):1107-12. PubMed ID: 19418054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mogamulizumab for the treatment of T-cell lymphoma.
    Makita S; Tobinai K
    Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
    Chau I; Harries M; Cunningham D; Hill M; Ross PJ; Archer CD; Norman AR; Wotherspoon A; Koh DM; Gill K; Uzzell M; Prior Y; Catovsky D
    Br J Haematol; 2003 Mar; 120(6):970-7. PubMed ID: 12648066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chemotherapy using gemcitabine hydrochloride for malignant lymphoma].
    Asou H; Maeda K; Takeuchi K; Kiyosawa K; Taniai H
    Gan To Kagaku Ryoho; 2013 Nov; 40(11):1489-95. PubMed ID: 24231701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
    Dong M; He XH; Liu P; Qin Y; Yang JL; Zhou SY; Yang S; Zhang CG; Gui L; Zhou LQ; Shi YK
    Med Oncol; 2013 Mar; 30(1):351. PubMed ID: 23269584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma.
    Kuruvilla J; Nagy T; Pintilie M; Tsang R; Keating A; Crump M
    Cancer; 2006 Jan; 106(2):353-60. PubMed ID: 16329112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: a prospective randomized trial in Algeria.
    Aribi M; Mesli N; Remla N; Sari BE; Taleb A; Touhami H; Bekadja MA; Zouaoui-Benhadji Z; Bouzid K; Meguenni K
    J Cancer Res Ther; 2010; 6(1):41-6. PubMed ID: 20479546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
    Remer M; Al-Shamkhani A; Glennie M; Johnson P
    Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
    Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
    Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
    Ng M; Waters J; Cunningham D; Chau I; Horwich A; Hill M; Norman AR; Wotherspoon A; Catovsky D
    Br J Cancer; 2005 Apr; 92(8):1352-7. PubMed ID: 15812553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma.
    Yao YY; Tang Y; Zhu Q; Zhuang Y; Cheng YM; Wang L; Zou LF
    Leuk Lymphoma; 2013 Jun; 54(6):1194-200. PubMed ID: 23061678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.